A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Medicine and Dentistry

• Poziotinib 100%
• Head and Neck Squamous Cell Carcinoma 60%
• Adverse Event 40%
• Multigene Family 40%
• Overall Survival 40%
• Exanthem 40%
• Progression Free Survival 40%
• Age 40%
• Tissues 40%
• Patient 40%
• Therapeutic Procedure 40%
• Clinical Trial 40%
• Capture 40%
• Biological Marker 20%
• Somatic Mutation 20%
• Malignant Neoplasm 20%
• Gene 20%
• Mucositis 20%
• Inpatient 20%
• Epidermal Growth Factor Receptor 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Poziotinib 100%
• Head and Neck Squamous Cell Carcinoma 60%
• Adverse Event 40%
• Overall Survival 40%
• Progression Free Survival 40%
• Rash 40%
• Chemotherapy 40%
• Biological Marker 20%
• Malignant Neoplasm 20%
• Mucosa Inflammation 20%